Achieve Life Sciences ( ) - 株価, ニュースと分析Nasdaq:ACHV

ACHV 株式概要

臨床段階の製薬会社であるアチーブメント・ライフサイエンシズ社は、禁煙とニコチン中毒のためのシチシニクリンを開発し、商品化している。

ACHV ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	5/6
配当金	0/6

報酬

当社が推定した公正価値より98.6%で取引されている

リスク分析

過去1年間で株主の希薄化は大幅に進んだ

収益が 100 万ドル未満 ( $0 )

現在は利益が出ておらず、今後3年間で利益が出る見込みはない

Achieve Life Sciences, Inc. 競合他社

Verastem

NasdaqCM:VSTM

US$150.5m

Sagimet Biosciences

NasdaqGM:SGMT

US$185.4m

Black Diamond Therapeutics

NasdaqGS:BDTX

US$183.9m

Adverum Biotechnologies

NasdaqCM:ADVM

US$160.6m

価格と性能

の歴代最高値、変動、値下がりまとめAchieve Life Sciences
過去の株価
現在の株価	US$5.12
52週高値	US$5.98
52週安値	US$3.03
ベータ	1.57
11ヶ月の変化	-0.39%
3ヶ月変化	13.53%
1年変化	19.07%
33年間の変化	-37.25%
5年間の変化	-69.16%
IPOからの変化	-99.42%

Recent updates

Achieve Life Sciences begins phase 2 trial testing cytisinicline for nicotine e-cigarette cessation

Jun 29

Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug

Apr 04

Is Achieve Life Sciences (NASDAQ:ACHV) Weighed On By Its Debt Load?

Mar 22

Is Achieve Life Sciences (NASDAQ:ACHV) In A Good Position To Deliver On Growth Plans?

Sep 27

We Think Achieve Life Sciences (NASDAQ:ACHV) Needs To Drive Business Growth Carefully

Jun 14

We're Keeping An Eye On Achieve Life Sciences' (NASDAQ:ACHV) Cash Burn Rate

Mar 01

Achieve Life Sciences prices stock offering at $7; shares down 2%

Dec 03

Achieve Life Sciences launches equity offering

Nov 30

株主還元

	ACHV	US Biotechs	US 市場
7D	8.2%	1.6%	2.3%
1Y	19.1%	23.6%	35.1%

業界別リターン: ACHV過去 1 年間で21.4 % の収益を上げたUS Biotechs業界を下回りました。

リターン対市場: ACHVは、過去 1 年間で31.5 % のリターンを上げたUS市場を下回りました。

価格変動

Is ACHV's price volatile compared to industry and market?
ACHV volatility
ACHV Average Weekly Movement	5.3%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

安定した株価: ACHV過去 3 か月間に大きな価格変動はありませんでした。

時間の経過による変動: ACHVの週次ボラティリティ ( 5% ) は過去 1 年間安定しています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
n/a	22	Rick Stewart	www.achievelifesciences.com

臨床段階の製薬会社であるアチーブメント・ライフサイエンシズ社は、禁煙とニコチン中毒のためのシチシニクリンの開発と商品化を行っている。シチシニクリンは植物由来のアルカロイドで、脳内のニコチン受容体と相互作用し、ニコチン離脱症状の重篤度を軽減する。Sopharma AD社およびUniversity of Bristolとライセンスおよび供給契約を結んでいる。

Achieve Life Sciences, Inc. 基礎のまとめ

Achieve Life Sciences の収益と売上を時価総額と比較するとどうか。
ACHV 基礎統計学
時価総額	US$166.56m
収益（TTM）	-US$27.54m
売上高(TTM)	n/a

0.0x

P/Sレシオ

-6.4x

PER（株価収益率

ACHV は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ACHV 損益計算書（TTM）
収益	US$0
売上原価	US$0
売上総利益	US$0
その他の費用	US$27.54m
収益	-US$27.54m

直近の収益報告

Jun 30, 2024

次回決算日

Nov 07, 2024

一株当たり利益（EPS）	-0.80
グロス・マージン	0.00%
純利益率	0.00%
有利子負債／自己資本比率	41.6%

ACHV の長期的なパフォーマンスは？

過去の実績と比較を見る

ACHV 株式概要

報酬

リスク分析

Achieve Life Sciences, Inc. 競合他社

NasdaqCM:VSTM

US$150.5m

NasdaqGM:SGMT

US$185.4m

NasdaqGS:BDTX

US$183.9m

NasdaqCM:ADVM

US$160.6m

価格と性能

最新ニュース

Achieve Life Sciences, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Achieve Life Sciences, Inc Promotes Jaime Xinos to Chief Commercial Officer

Achieve Life Sciences, Inc. Announces Appointment of Mark L. Rubinstein as Head of Medical Affairs

Achieve Life Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

New minor risk - Profitability

Achieve Life Sciences, Inc. Announces CEO Changes

Recent updates

Achieve Life Sciences, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Achieve Life Sciences, Inc Promotes Jaime Xinos to Chief Commercial Officer

Achieve Life Sciences, Inc. Announces Appointment of Mark L. Rubinstein as Head of Medical Affairs

Achieve Life Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

New minor risk - Profitability

Achieve Life Sciences, Inc. Announces CEO Changes

New minor risk - Profitability

Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence

Achieve Life Sciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Achieve Life Sciences: 1st Half 2025 NDA Filing On Track With FDA Agreement

Achieve Life Sciences, Inc. Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes

New minor risk - Profitability

Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine

Achieve Life Sciences, Inc., Annual General Meeting, Jun 05, 2024

Achieve Life Sciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Price target decreased by 17% to US$19.71

Achieve Life Sciences, Inc. Announces Data from Cytisinicline ORCA Program to Be Presented at the 2024 Society for Research on Nicotine and Tobacco Annual Meeting

Achieve Life Sciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New major risk - Financial position

Achieve Life Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $60.000002 million.

Does Achieve Life Sciences (NASDAQ:ACHV) Have A Healthy Balance Sheet?

New minor risk - Profitability

Price target decreased by 12% to US$24.71

New minor risk - Share price stability

Price target decreased by 8.1% to US$27.57

Achieve Life Sciences, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Is Achieve Life Sciences (NASDAQ:ACHV) Using Debt In A Risky Way?

Achieve Life Sciences, Inc. Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting

New minor risk - Market cap size

New major risk - Financial position

Achieve Life Sciences, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)

Achieve Life Sciences, Inc. Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial

Forecast to breakeven in 2025

Price target increased by 10% to US$27.43

Executive Chairman exercised options and sold US$69k worth of stock

High number of new directors

Is Achieve Life Sciences (NASDAQ:ACHV) A Risky Investment?

Price target increased by 14% to US$28.33

Achieve Life Sciences, Inc. Announces Last Subject Dosed in Phase 2 Orca-V1 Trial of Cytisinicline for E-Cigarette Cessation

Dialectic Capital Engages in Discussions with Achieve Life Sciences

Achieve Life Sciences, Inc. Announces That the Final Subject of the Company’s Phase 3 ORCA-3 Trial Has Completed Treatment in the Study

Achieve Life Sciences, Inc. Receives Written Notification from the Listing Qualifications Staff of the Nasdaq Stock Market

Consensus revenue estimates fall by 33%

Price target decreased to US$28.13

Achieve Life Sciences, Inc. announced that it expects to receive CAD 18.930777 million in funding

Achieve Life Sciences, Inc. Announces Early Completion of Target Enrollment in Cytisinicline E-Cigarette Cessation Trial

Achieve Life Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

Consensus revenue estimates fall by 33%

Achieve Life Sciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine E-Cigarette Cessation

Achieve Life Sciences begins phase 2 trial testing cytisinicline for nicotine e-cigarette cessation

Achieve Life Sciences Inc. Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine E-Cigarette Users

Price target increased to US$34.13

Achieve Life Sciences Announces Positive Topline Results from Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers

Price target decreased to US$31.50

Achieve Life Sciences, Inc. to Report Q1, 2022 Results on May 12, 2022

Achieve Life Sciences, Inc., Annual General Meeting, May 31, 2022